ELI LILLY & CO raised its 2026 adjusted profit forecast to $35.50–$37.00 per share after beating first-quarter earnings expectations. Q1 adjusted profit reached $8.55 per share, exceeding the $6.66 estimate as Mounjaro sales hit $8.7B. Investors are tracking whether Lilly can maintain volume growth to offset lower drug prices in the United_States.

International Demand Drives Earnings Beat